Klarovel Medical Advisory Board

What the Advisory Board does

The Klarovel Medical Advisory Board is the editorial review function that signs off every long-form Klarovel post before publication. Its job is to make sure that what readers see is anchored in primary literature, accurate against current regulation, and free of the kinds of medical-claim drift that tend to creep into peptide content elsewhere on the web.

The review process

Each post passes four checks before it ships:

1. Claim sourcing. Every load-bearing factual claim must trace to a peer-reviewed primary source, a regulator publication (FDA, EMA, Helsedirektoratet, Legemiddelverket, FHI), or an authority equivalent. Reddit, Wikipedia, social posts, and unsourced blogs are deny-listed.
2. Dose verification. Any dose appearing in the post is cross-checked against the Klarovel peptide research catalogue. We do not publish dose ranges that are not already in the catalogue, and we do not publish dosing guidance for human use.
3. Regulatory accuracy. When a post touches jurisdiction-specific rules (importation, scheduling, approval status), the relevant regulator's current guidance is the source of truth. Outdated regulatory framing is a hard block on publication.
4. Tone and compliance. Banned medical-claim language (cures, treats, prevents, breakthrough) is filtered out by an automated audit and a human review pass. The required wellness disclaimer must be present before the closing section of every post.

Each post carries the date of its most recent review. When any of the four checks would now fail, the post is re-reviewed and the review date updated, regardless of whether it is on its regular refresh cadence.

Composition

The Advisory Board is composed of medical and scientific professionals consulted by Klarovel on a content-by-content basis, alongside Klarovel's in-house editorial reviewers. Specialty consults are scoped to the topic of each post (for example, endocrinology for GLP-1 content, sports medicine for healing peptides, cognitive neuroscience for nootropic peptides).

We do not, at this stage, publish the names of individual reviewers. We hold this position deliberately rather than listing names that could not be independently verified by readers. As the platform matures, named reviewer attribution will replace the collective byline.

What this is not

The Advisory Board is an editorial quality function. It does not prescribe. It does not provide medical advice to readers directly. It does not endorse any individual reader's decision to use, source, or research a peptide. The disclaimers on every post are not boilerplate; they are the operative limits of what Klarovel content is.

Reader feedback

If you spot a load-bearing claim that you can show is incorrect, write to editorial at klarovel dot com with the post URL and a citation to the corrected fact. We act on these quickly. See our disclosures page for the full editorial and affiliate posture.